title: MiR-139-5p inhibits the biological function of breast cancer cells by targeting Notch1 and mediates chemosensitivity to docetaxel.
abstract: OBJECTIVE
  MiRNA-139 is located at 11q13.4 and it has anti-oncogenic and antimetastatic activity in humans. However, its role in controlling apoptosis, invasion and metastasis and the development of chemosensitivity to docetaxel in breast cancer cells are not fully understood. The aim of this study was to research the biological function of miR-139-5p and the efficacy of chemosensitivity to docetaxel.
  
  
  METHODS
  MiR-139-5p expression in MCF-7, MCF-7/Doc cells and in selected breast cancer tissue samples was confirmed by real-time PCR; cell viability was analyzed by Cell Counting Kit-8 assay; apoptosis and cell cycle were analyzed by flow cytometry; control of metastasis and invasion of breast cancer cells was measured by transwell assay; expression of Notch1 was measured by western blot; a luciferase reporter vector was constructed to identify the miR-139-5p target gene.
  
  
  RESULTS
  MiR-139-5p was significantly down-regulated in breast cancer cells. MiR-139-5p inhibits the viability of breast cancer cells. MiR-139-5p induces apoptosis, causes cell cycle arrest in S phase, inhibits migration and invasion in breast cancer cells, however, MiR-139-5p play the opposite role in docetaxel-induced breast cancer cells.
  
  
  CONCLUSIONS
  MiR-139-5p not only attenuated the development of breast cancer cells but also mediated drug-resistance by regulating the expression of the downstream target gene Notch1.
authors: Department of General Surgery, Xuzhou Medical College, Xuzhou, Jiangsu, China; Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital, Cancer Institute of Jiangsu Province, Nanjing, Jiangsu, China. Electronic address: zhanghedazhd@163.com.
authors: He-da
authors: HD
authors: Zhang
authors: Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital, Cancer Institute of Jiangsu Province, Nanjing, Jiangsu, China; Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
authors: Da-Wei
authors: DW
authors: Sun
authors: Department of General Surgery, Huai an Second People's Hospital, Xuzhou Medical College, Huai'an, Jiangsu, China.
authors: Ling
authors: L
authors: Mao
authors: Anhui University of Chinese Medicine, Anhui, China.
authors: Jun
authors: J
authors: Zhang
authors: Xuzhou Infectious Disease Hospital, Xuzhou, Jiangsu, China.
authors: Lin-Hong
authors: LH
authors: Jiang
authors: Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital, Cancer Institute of Jiangsu Province, Nanjing, Jiangsu, China.
authors: Jian
authors: J
authors: Li
authors: Nanjing Medical University, Nanjing, Jiangsu, China.
authors: Ying
authors: Y
authors: Wu
authors: Department of General Surgery, Xuzhou Medical College, Xuzhou, Jiangsu, China.
authors: Hao
authors: H
authors: Ji
authors: Department of General Surgery, Xuzhou Medical College, Xuzhou, Jiangsu, China.
authors: Wei
authors: W
authors: Chen
authors: Nanjing Medical University, Nanjing, Jiangsu, China.
authors: Jing
authors: J
authors: Wang
authors: Research Center of Clinical Oncology, The Affiliated Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
authors: Rong
authors: R
authors: Ma
authors: Research Center of Clinical Oncology, The Affiliated Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
authors: Hai-Xia
authors: HX
authors: Cao
authors: Research Center of Clinical Oncology, The Affiliated Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
authors: Jian-Zhong
authors: JZ
authors: Wu
authors: Department of General Surgery, Nanjing Medical University Affiliated Cancer Hospital, Cancer Institute of Jiangsu Province, Nanjing, Jiangsu, China. Electronic address: jinhaitang1@hotmail.com.
authors: Jin-Hai
authors: JH
authors: Tang
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000235:genetics; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D059447:Cell Cycle Checkpoints / Q000235:genetics; D049109:Cell Proliferation / Q000235:genetics; D002470:Cell Survival / Q000235:genetics; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D055785:Gene Knockdown Techniques; D006801:Humans; D061986:MCF-7 Cells; D035683:MicroRNAs / Q000235:genetics* / Q000378:metabolism; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012334:RNA, Neoplasm / Q000235:genetics / Q000378:metabolism; D051881:Receptor, Notch1 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction; D043823:Taxoids / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; C555098:MIRN139 microRNA, human; D035683:MicroRNAs; C497761:NOTCH1 protein, human; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D051881:Receptor, Notch1; D043823:Taxoids; D000077143:Docetaxel
keywords: Breast cancer; Chemoresistance; Notch1; miRNA 139-5p